Company intelligence / Profile preview

CureTech Solutions

Ownership: Private
Development stage: Other

Overview

CureTech developed broad-spectrum, immune-modulating therapies for cancer. Its lead product was CT-011, a humanized monoclonal antibody targeting PD‑1, which reached Phase 2 clinical testing. The company also worked on peptide-based vaccines to modulate anti-cancer immune responses. Clinical results focused on efficacy and safety in oncology indications such as post-stem cell transplantation.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyPeptide-based vaccine
Industry: Biotech

Beyond the preview

Go deeper on CureTech Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CureTech Solutions.

Explore the full profile